Logo image of VNRX

VOLITIONRX LTD (VNRX) Stock Price, Quote, News and Overview

NYSEARCA:VNRX - NYSE Arca - US9286611077 - Common Stock - Currency: USD

0.5389  +0.01 (+2.12%)

After market: 0.5129 -0.03 (-4.82%)

VNRX Quote, Performance and Key Statistics

VOLITIONRX LTD

NYSEARCA:VNRX (6/3/2025, 5:05:00 PM)

After market: 0.5129 -0.03 (-4.82%)

0.5389

+0.01 (+2.12%)

Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Supplies
Statistics
52 Week High0.9
52 Week Low0.4
Market Cap55.52M
Shares103.02M
Float82.86M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12/amc
IPO02-06 2015-02-06


VNRX short term performance overview.The bars show the price performance of VNRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20

VNRX long term performance overview.The bars show the price performance of VNRX in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of VNRX is 0.5389 USD. In the past month the price increased by 7.76%. In the past year, price decreased by -20.74%.

VOLITIONRX LTD / VNRX Daily stock chart

VNRX Competitors/Peers

The largest stocks on the US markets in the "Health Care Supplies" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ALC ALCON INC 28.48 42.69B
COO COOPER COS INC/THE 17.24 13.38B
ALGN ALIGN TECHNOLOGY INC 19.2 12.99B
SOLV SOLVENTUM CORP 12.48 12.85B
MMSI MERIT MEDICAL SYSTEMS INC 26.5 5.59B
LNTH LANTHEUS HOLDINGS INC 11.74 5.38B
BLCO BAUSCH + LOMB CORP 23.96 4.06B
HAE HAEMONETICS CORP/MASS 15.24 3.35B
ICUI ICU MEDICAL INC 18.7 3.21B
XRAY DENTSPLY SIRONA INC 9.46 3.17B
UFPT UFP TECHNOLOGIES INC 29.24 1.84B
NEOG NEOGEN CORP 15.79 1.30B

About VNRX

Company Profile

VNRX logo image VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. The company is headquartered in Henderson, Nevada and currently employs 85 full-time employees. The company went IPO on 2015-02-06. The firm is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.

Company Info

VOLITIONRX LTD

1489 West Warm Springs Road, Suite 110

Henderson NEVADA 78738 US

CEO: Cameron Reynolds

Employees: 85

VNRX Company Website

VNRX Investor Relations

Phone: 16466501351

VOLITIONRX LTD / VNRX FAQ

What is the stock price of VOLITIONRX LTD today?

The current stock price of VNRX is 0.5389 USD. The price increased by 2.12% in the last trading session.


What is the ticker symbol for VOLITIONRX LTD stock?

The exchange symbol of VOLITIONRX LTD is VNRX and it is listed on the NYSE Arca exchange.


On which exchange is VNRX stock listed?

VNRX stock is listed on the NYSE Arca exchange.


What is the price forecast or stock price prediction for VOLITIONRX LTD stock?

10 analysts have analysed VNRX and the average price target is 3.22 USD. This implies a price increase of 497.16% is expected in the next year compared to the current price of 0.5389. Check the VOLITIONRX LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VOLITIONRX LTD worth?

VOLITIONRX LTD (VNRX) has a market capitalization of 55.52M USD. This makes VNRX a Micro Cap stock.


How many employees does VOLITIONRX LTD have?

VOLITIONRX LTD (VNRX) currently has 85 employees.


What are the support and resistance levels for VOLITIONRX LTD (VNRX) stock?

VOLITIONRX LTD (VNRX) has a support level at 0.48 and a resistance level at 0.58. Check the full technical report for a detailed analysis of VNRX support and resistance levels.


Is VOLITIONRX LTD (VNRX) expected to grow?

The Revenue of VOLITIONRX LTD (VNRX) is expected to grow by 346.89% in the next year. Check the estimates tab for more information on the VNRX EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy VOLITIONRX LTD (VNRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VOLITIONRX LTD (VNRX) stock pay dividends?

VNRX does not pay a dividend.


When does VOLITIONRX LTD (VNRX) report earnings?

VOLITIONRX LTD (VNRX) will report earnings on 2025-08-12, after the market close.


What is the Price/Earnings (PE) ratio of VOLITIONRX LTD (VNRX)?

VOLITIONRX LTD (VNRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.27).


What is the Short Interest ratio of VOLITIONRX LTD (VNRX) stock?

The outstanding short interest for VOLITIONRX LTD (VNRX) is 0.42% of its float. Check the ownership tab for more information on the VNRX short interest.


VNRX Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to VNRX. When comparing the yearly performance of all stocks, VNRX is a bad performer in the overall market: 81.07% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

VNRX Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to VNRX. Both the profitability and financial health of VNRX have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VNRX Financial Highlights

Over the last trailing twelve months VNRX reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS increased by 41.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -281.97%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%40%
Sales Q2Q%43.41%
EPS 1Y (TTM)41.3%
Revenue 1Y (TTM)62.43%

VNRX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to VNRX. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 57.23% and a revenue growth 346.89% for VNRX


Ownership
Inst Owners20.36%
Ins Owners8.19%
Short Float %0.42%
Short Ratio1.3
Analysts
Analysts80
Price Target3.22 (497.51%)
EPS Next Y57.23%
Revenue Next Year346.89%